10 Liver Cancer Clinical Trials in Baltimore, MD (2026)

Q: How do I join a clinical trial in Baltimore?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you.

Recruiting Liver Cancer Studies in Baltimore

NCT06726161Recruiting

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC...

Baltimore, MDPHASE1590 participantsRayzeBio, Inc.

View Study Details

NCT06795022Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced o...

Baltimore, MDPHASE1304 participantsAstraZeneca

View Study Details

NCT07175441Recruiting

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

RBS2418 is a targeted immune modulator that inhibits ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1). It is designed to promote anti-tumor immunity by preserving endogenous 2'-3' cyclic gua...

Baltimore, MDPHASE2220 participantsRiboscience, LLC.

View Study Details

NCT05440708Recruiting

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unrese...

Baltimore, MDPHASE1193 participantsTvardi Therapeutics, Incorporated

View Study Details

NCT04078230Recruiting

Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma (ICC) is one of the common malignant tumors. Lymph node metastasis is an important factor affecting the poor prognosis of intrahepatic cholangiocarcinoma. The eighth ed...

Baltimore, MDNA168 participantsSecond Affiliated Hospital, School of Medicine, Zhejiang University

View Study Details

NCT06915753Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, includin...

Baltimore, MDPHASE1100 participantsTyra Biosciences, Inc

View Study Details

NCT05733598Recruiting

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab in the second line setting for locally advanced unresectable, recurrent, and/or ...

Baltimore, MDPHASE260 participantsReplimune Inc.

View Study Details

NCT04248569Recruiting

DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with un...

Baltimore, MDPHASE156 participantsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

View Study Details

NCT06728293Recruiting

Effect of the HCC Liver-Link Intervention

This study is a pilot, multi-center randomized controlled trial testing the HCC Liver-Link intervention, a culturally tailored, multi-level program designed to reduce racial disparities in hepatocellu...

Baltimore, MDNA40 participantsIndiana University

View Study Details

NCT06027086Recruiting

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

The purpose of this study is to determine whether the combination of subcutaneous DRP-104 in combination with intravenous Durvalumab is safe and yields a clinically compelling antitumor activity measu...

Baltimore, MDPHASE127 participantsSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

View Study Details

About Liver Cancer Clinical Trials in Baltimore

Liver cancer most commonly presents as hepatocellular carcinoma (HCC) and is often associated with chronic liver disease or hepatitis. It is one of the fastest-growing causes of cancer death. Treatment options include surgery, liver transplant, ablation, and systemic therapies.

There are currently 10 liver cancer clinical trials recruiting participants in Baltimore, MD. These studies are seeking a combined 1,758 participants. Research is being sponsored by RayzeBio, Inc., AstraZeneca, Riboscience, LLC. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Liver Cancer Clinical Trials in Baltimore — FAQ

Are there liver cancer clinical trials in Baltimore?

Yes, there are 10 liver cancer clinical trials currently recruiting in Baltimore, MD. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Baltimore?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Baltimore research site will contact you about next steps.

Are clinical trials in Baltimore free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Baltimore studies also compensate for your time and travel.

What liver cancer treatments are being tested?

The 10 active trials in Baltimore are testing new therapies including novel drugs, biologics, and treatment approaches for liver cancer.

Data updated July 18, 2026 from ClinicalTrials.gov